Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Bertele

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|September 11, 2001
New approach to clinical trials and drug registration. Author's suggestions for drug approval are questionableS Garattini, V Bertele'
Lancet (London, England)|March 27, 1999
Multicentre clinical trialsS Garattini, V Bertele
European Journal of Clinical Pharmacology|September 29, 2000
Policing the European pharmaceutical market's prioritiesS Garattini, V Bertele'
Lancet (London, England)|July 17, 2001
Adjusting Europe's drug regulation to public health needsS Garattini, V Bertele
European Journal of Pharmacology|December 3, 1982
Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclinV Bertele, G De Gaetano
Heart (British Cardiac Society)|September 9, 2000
Inconclusive messages from equivalence trials in thrombolysisV Bertele, V Torri, S Garattini
Agents and Actions. Supplements|January 1, 1986
Mode of action of currently used antiplatelet drugsG de Gaetano, V Bertele', C Cerletti
Agents and Actions. Supplements|January 1, 1992
Pathophysiology of critical leg ischaemia and mode of action of prostaglandinsV Bertele, C Cerletti, G de Gaetano
British Journal of Cancer|September 2, 2005
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressuresG Apolone, R Joppi, V Bertele', et al.
Journal of Thrombosis and Haemostasis : JTH|December 23, 2011
Solicited self-referencing undermines the credibility of researchers and journalsF Avanzini, V Bertele, V Pistotti, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|September 11, 2001
New approach to clinical trials and drug registration. Author's suggestions for drug approval are questionableS Garattini, V Bertele'
Lancet (London, England)|March 27, 1999
Multicentre clinical trialsS Garattini, V Bertele
European Journal of Clinical Pharmacology|September 29, 2000
Policing the European pharmaceutical market's prioritiesS Garattini, V Bertele'
Lancet (London, England)|July 17, 2001
Adjusting Europe's drug regulation to public health needsS Garattini, V Bertele
European Journal of Pharmacology|December 3, 1982
Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclinV Bertele, G De Gaetano
Heart (British Cardiac Society)|September 9, 2000
Inconclusive messages from equivalence trials in thrombolysisV Bertele, V Torri, S Garattini
Agents and Actions. Supplements|January 1, 1986
Mode of action of currently used antiplatelet drugsG de Gaetano, V Bertele', C Cerletti
Agents and Actions. Supplements|January 1, 1992
Pathophysiology of critical leg ischaemia and mode of action of prostaglandinsV Bertele, C Cerletti, G de Gaetano
British Journal of Cancer|September 2, 2005
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressuresG Apolone, R Joppi, V Bertele', et al.
Journal of Thrombosis and Haemostasis : JTH|December 23, 2011
Solicited self-referencing undermines the credibility of researchers and journalsF Avanzini, V Bertele, V Pistotti, et al.
Pageof 2